TRINCE
LIVE

Serial Number

79366929

Owner

Trince, besloten vennootschap

Attorney

Clifford D Hyra

Filing Date

Feb 14, 2023

Add to watchlist:

No watchlists yet
View on USPTO

TRINCE Trademark

Serial Number: 79366929 • Registration: 7592335

TRINCE is a trademark filed by Trince, besloten vennootschap on February 14, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 37 (Building & Construction), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Trince, besloten vennootschap (3 trademarks)

Ottergemsesteenweg-Zuid 731

Entity Type: 99

Trademark Details

Filing Date

February 14, 2023

Registration Date

December 10, 2024

Published for Opposition

October 8, 2024

Goods & Services

Cells for medical or clinical use; personalized autologous or allogeneic cell-based therapies in the nature of cells for medical use; biological preparations for use in cell cultures for medical applications; pharmaceutical preparations and substances for the treatment of genetic diseases in the nature of single-gene disorders, immunological diseases and cancer; pharmaceutical preparations and substances for applications in tissue engineering and regenerative medicine for cell transplantation, stem cell therapy and gene therapy; reagents for medical use; biological reagents for medical use; diagnostic reagents for medical use; reagents for use in medical genetic testing; stem cells for medical purposes; engineered medicinal cell-based products, cell lines and biomolecules, namely, genetically engineered cells for medical use; medical reagents contained in a cartridge for medical diagnostic use

Scientific research and consultation services in the field of cell modification; research and development services in the field of cell therapies; biological and medical research and consultation services related thereto in the field of cell modification; product research and development in the fields of biology and medical sciences; providing laboratory research services in the field of gene expression; providing medical research information in the field of cancer and cell therapy related thereto; medical and scientific research services related to the use of human stem cells for therapeutic purposes; Scientific research services for others in the fields of oncology, immunotherapy treatments, tissue engineering, regenerative medicine and biological cell modification procedures; medical laboratory services; development of cell therapies using genetic cell modification technology; development of gene modified cell therapies; research and development in the pharmaceutical and biotechnology fields; laboratory analysis and industrial research services in the medical, biotechnological, nanomaterials and pharmaceutical fields

Scientific apparatus and instruments for cell modification, namely, transfection devices; scientific apparatus and instruments for scientific research and development, namely, transfection devices for cell modification; scientific apparatus and instruments for scientific research and development, namely, devices for transfection of cells for clinical research and medical research; Scientific apparatus and instruments for use in cell therapy, stem cell therapy, tissue engineering and regenerative medicine, namely, devices for the ablation and killing of cells; laboratory instruments for use in immunotherapy and cancer treatment, namely, transfection devices; laboratory instruments for use in tissue engineering and regenerative medicine, namely, devices for transfection, cell and tissue ablation and cell killing; laboratory instruments for the development of gene modified cell therapies, namely, transfection devices; laboratory equipment for modification of cells for research related to the treatment of diseases, namely, devices for transfection, cell ablation and cell killing; equipment for cell manipulation, namely, devices for transfection, cell ablation and cell killing

Educational services, namely, conducting classes, seminars, courses and workshops in the medical, pharmaceutical and scientific fields; educational services in the field of genetic medicine and therapies, cell therapies and gene-modified cell therapies rendered through face-to-face and web-based courses, seminars, workshops and training sessions; training services in the medical, pharmaceutical and scientific fields; Training in the use and operation of scientific apparatus for cell modification and scientific apparatus and instruments for scientific research and development; organization and conducting of workshops in the medical, pharmaceutical and scientific fields; publication of books in the medical, pharmaceutical and scientific fields; providing online non-downloadable electronic publications in the nature of books, magazines, journals, articles and manuals featuring information relating to the medical, pharmaceutical and scientific fields

Installation, maintenance, and repair of medical apparatus and instruments; installation, maintenance and repair of laboratory apparatus and instruments; installation, maintenance, and repair of scientific apparatus and instruments for scientific research and development in the field of cell modification, cell therapies, stem cell therapy, tissue engineering and regenerative medicine; provision of information relating to the installation, maintenance, and repair of medical apparatus and instruments, laboratory apparatus and instruments, and scientific apparatus and instruments for scientific research and development in the field of cell modification, cell therapies, stem cell therapy, tissue engineering and regenerative medicine

Medical devices, namely, transfection devices used for cell therapy treatments; Medical devices, namely, instruments used for immunotherapy treatments and for modifying cells for the treatment of cancer and other diseases and medical conditions related to tissue engineering and regenerative medicine namely, devices for transfection, cell ablation and cell killing; apparatus for the regeneration of stem cells and tissues for medical purpose; medical apparatus and instruments for use in cell therapy, stem cell therapy, tissue engineering and regenerative medicine, namely, devices for transfection, cell ablation and cell killing; unfilled cartridges for cell transfection, cell ablation and cell killing for medical diagnostic purposes

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 31, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 9, 2025 FICS
FINAL DISPOSITION PROCESSED
May 9, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 10, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 10, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 8, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 8, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 20, 2024 OPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 18, 2024 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 4, 2024 OPNS
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 4, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 4, 2024 TEME
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 4, 2024 OPNR
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 3, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 3, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
May 1, 2024 GNFN
FINAL REFUSAL E-MAILED
May 1, 2024 GNFR
FINAL REFUSAL WRITTEN
May 1, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 2, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 2, 2024 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 21, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Dec 21, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 21, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 21, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 21, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 21, 2023 COAR
REFUSAL PROCESSED BY IB
Dec 12, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 22, 2023 RFCS
REFUSAL PROCESSED BY MPU
Nov 22, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 21, 2023 RFCR
NON-FINAL ACTION WRITTEN
Nov 20, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 14, 2023 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Jun 4, 2023 NREP
APPLICATION FILING RECEIPT MAILED
Apr 14, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 10, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 6, 2023 REPR